Hbm Holdings Ltd. · HKEX:2142
Hbm — FY2023 Earnings Presentation
37 slides from Hbm's earnings presentation, Mar 28, 2024
Slide 1: FY2023 Results
FY2023 RESULTS March 28, 2024 HBM HOLDINGS-B 2142-HK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by HBM Holdings Limited (the “Company”) solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into in
Slide 3: Agenda
Agenda HBM Holdings: Jingsong Wang MD PhD 01 Value Creation through Globalization and Sustainable Growth Harbour Therapeutics: Xiaolu Tao PhD / Yiping Rong PhD 02 Efficient and Synergized Pipeline Advancement Nona Biosciences: 03 Strong Growth Empowered by Innovation Yun He PhD Partnerships: 04 Inno
Slide 4: HBM Holdings: Value Creation through Globalization and Sustainable Growth
HBM Holdings： Value Creation through Globalization and Sustainable Growth Dr. Jingsong Wang Founder, Chairman of the Board and Chief Executive Officer
Slide 5: HBM Holdings: Value Creation through Globalization and Sustainable Growth
HBM Holdings: Value Creation through Globalization and Sustainable Growth Focus on China with global perspective 1 Sustainable Growth: and steadily advance core pipeline assets 6 milestones from key clinical-stage 5 drugs obtained IND approval: 7 milestones from collaboration assets: assets: ● HBM10
Slide 6: Harbour Therapeutics: Efficient and Synergized Pipeline Advancement
Harbour Therapeutics: Efficient and Synergized Pipeline Advancement Dr. Xiaolu Tao Dr. Yiping Rong President of Harbour Therapeutics Executive Director, Chief Scientific Officer
Slide 7: Harbour Therapeutics – FY23 Business Highlights
Harbour Therapeutics – FY23 Business Highlights Clinical Stage Assets Collaboration Assets Preclinical Stage Assets Batoclimab (HBM9161), gMG： 1 regional license-out to accelerate Advancing global pipeline of highly - Completion of phase III clinical trial global R&D differentiated next-gen th
Slide 8: Highly Innovative and Differentiated Global Pipeline
Highly Innovative and Differentiated Global Pipeline Commercial Status Project Target Indication Rights Discovery Pre-Clinical IND Phase I Phase II Phase III BLA Batoclimab Greater China Rights FcRn Myasthenia Gravis Phase III HBM9161 Out-licensed1 Solid Tumors a Monotherapy Ph 1b/2 Porustobart Comb
Slide 9: Batoclimab (HBM9161) Demonstrates Remarkable Therapeutic Benefits in gMG Patients
Batoclimab (HBM9161) Demonstrates Remarkable Therapeutic Benefits in gMG Patients Highlights • First and only innovative drug targeting FcRn that has completed phase I,II and III clinical trials in China • First innovative drug for gMG that has been granted breakthrough therapy designation by CDE •
Slide 10: Ph III Study Results of Batoclimab (HBM9161) Published in JAMA Neurology
Ph III Study Results of Batoclimab (HBM9161) Published in Top Medical Journal – JAMA Neurology JAMA Neurology (March 2024) Clinial Data demonstrate the efficacy and safety of Batoclimab in adult patients with generalized MG The MG-ADL score diverged between antibody-positive patient group and pl
Slide 11: Porustobart (HBM4003) Clinical Benefit and Market Opportunities in Various Tumors
Porustobart (HBM4003) Clinical Benefit and Market Opportunities in Various Tumors Robust efficacy observed for HBM4003 + Toripalimab Excellent therapeutic potential observed for in PD-1 naïve melanoma cohort HBM4003 in patients with HCC Best Overall Response by RECIST 1.1, N (%) • HBM4003 monotherap
Slide 12: Porustobart (HBM4003) – Pivotal Trial Preparations
Porustobart (HBM4003) – Pivotal Trial Preparations Proof of concept in Preparation for Late- Step Step Further verification Step 1 previously treated 2 3 stage clinical trial in in selected solid tumors advanced solid tumor certain indications Registration studies Melanoma Objective responses • Mela
Slide 13: HBM1020 (B7H7/HHLA2) An Alternative Immune Escape Mechanism Beyond PD-L1
HBM1020 (B7H7/HHLA2) An Alternative Immune Escape Mechanism Beyond PD-L1 Highlights • T cell and NK cell activation activity and excellent in vivo efficacy in humanized tumor models • Widely Expressed in Various Solid Tumors & Reciprocal to the Expression of PD-L1 • Huge potential to treat PD-L1 neg
Slide 14: Building The Technical Foundations on Immune Cell Engager Bispecifics
Building The Technical Foundations on Immune Cell Engager Bispecifics Partnerships based on Immune Cell Engager Bispecifics NK Cell Engager T Cell Engager HBICE targeting four types of immune cells MΦ Engager DC Engager 14
Slide 15: HBM9027 (PD-L1xCD40) Innovative Bispecific Antibody Activating APC/T Cells
HBM9027 (PD-L1xCD40) Innovative Bispecific Antibody Activating APC/T Cells Highlights • Synergistically activating both myeloid/DC cells and T cells is critical for some solid tumor therapy considering the most abundant myeloid cell population in TME • Well maintained αPD-L1 arm and αCD40 arm functi
Slide 16: HBM7004 (B7H4xCD3) Unique 2+1 Asymmetric HBICE
HBM7004 (B7H4xCD3) Unique “2+1” Asymmetric HBICE® Using Novel TAA and Safer Anti-CD3 Arm Highlights • HBICE® technology grants asymmetric structure but less light chain mispairings • TAA is mainly expressed in low PD-L1 tumors, particularly in gynecological cancers and squamous cell lung cancer • Po
Slide 17: Nona Biosciences: Strong Growth Empowered by Innovation
Nona Biosciences: Strong Growth Empowered by Innovation Dr. Yun He Chief Technology Officer, Nona Biosciences
Slide 18: Nona Biosciences Empowers Global Therapeutic Innovation
Nona Biosciences Empowers Global Therapeutic Innovation Our Mission Nona: Roman Goddess Leveraging industrial leading technology platforms, Nona Biosciences is committed to provide Who Enables integrated discovery solutions for biotech and pharmaceutical companies from Idea to IND (I to I) Others to
Slide 19: Nona's Technology Platform Contributes to the Rapid Business Growth Achieved in FY23
Nona’s Technology Platform Contributes to the Rapid Business Growth Achieved in FY23 Platform-based Research Services 50+ 19+ Protein partners Conjugation Delivery Cell Therapy projects entered Engineering Technology Technology Technology 30+ into clinical stage collaborations in progress Technology
Slide 20: Nona's Unique Growth Model Based on Platform Technology
Nona’s Unique Growth Model Based on Platform Technology As the # of platform-based As the platform-based collaborations increases collaborations progress 2023 2024E Royalties Milestones Upfront payments Platform-based Research Service Revenue Note: The above figure is for illustrative purposes only
Slide 21: Harbour Mice - New Generation of Fully Human Antibody Platforms
Harbour Mice®- New Generation of Fully Human Antibody Platforms Harbour Mice® Fully Human Antibody Transgenic Mice AI+ Ab discovery Infectious disease H2L2 HCAb Delivery Protein Technology Engineering Cell Therapy Technology Conjugation Technology Human Natural Optimized Validated Radionuclide sdAb
Slide 22: Extend Antibody Discovery Platform to Integrated ADC Discovery Platform
Extend Antibody Discovery Platform to Integrated ADC Discovery Platform H2L2 HCAb BsAb Clinically validated fully human antibody Comprehensive physicochemical characterization Efficacy studies in various tumor models; PK platform of ADC molecules studies; Preliminary toxicities. In vitro In vivo Tar
Slide 23: Explore Frontiers in ADC Field
Explore Frontiers in ADC Field Collaborate with global ADC experts to Unveil the advantages of Application of HCAb in XDC for build ADC ecosystem bispecific / biparatopic ADC Diagnosis & Therapy Radiolabeled anti-MSLN HCAb can quickly penetrate into tumors bsAb showed stronger internalization full
Slide 24: Comprehensive Bispecific Antibody Discovery Workflow to Reinforce HBICE Platform
Comprehensive Bispecific Antibody Discovery Workflow to Reinforce Industry- leading HBICE® Platform (HCAb Based Immune Cell Engagers) bsAb Engineering & Antibody Discovery bsAb Format Screening Candidate Selection characterization Functional activity 3000 Tumor inhibition 100 2500 80 Cytotoxicity %
Slide 25: Combine mRNA & HBICE Technologies to Create Next-Gen Therapeutics
Combine mRNA & HBICE® Technologies to Create Next-Gen Therapeutics HBICE® RiboHBICE® Anti-TAA x 2 Anti-CD3 HBICE-4 HBICE-4-mRNA RiboHBICE® demonstrates stronger RiboHBICE® shows longer serum half- Longer serum half-life translates to tumor inhibition and longer duration life than recombinant protein
Slide 26: HCAb High-efficiency CAR-T Functional Screening Platform
HCAb High-efficiency CAR-T Functional Screening Platform Boosts the Innovation of Cell Therapies Immunization HCAb VH-CAR HCAb VH-CAR HCAb Harbour Mice® lentivector library lentivirus library HCAb VH derived CAR-T showed superior cytotoxicity and induce more cytokine release than reference scFv VH F
Slide 27: Nona's Technology Platform is Open to the Entire Industry
Nona’s Technology Platform is Open to the Entire Industry • Protein • Antibody production • Affinity maturation • Cell line • Binding/affinity/specificity • Fc engineering • DNA • In vitro functional assay • Liability engineering • mRNA • Developability • Bispecific engineering Immunization Characte
Slide 28: Partnerships: Innovative Platform Endorsed by Global Leading Players
Partnerships: Innovative Platform Endorsed by Global Leading Players Mr. Youchen Chen VP, Corporate Development and Investor Relations
Slide 29: Continuous Endorsement from Global Leading Pharma as Validation of Our Platform
Continuous Endorsement from Global Leading Pharma as A Strong Validation of Our Technology Platform mRNA Delivery 2024 Global development HBM7022 Bispecific antibody US$500m+ out-license total size 1st Chinese to "go global" COVID-19 Neutralizing Ab out-license US$350m+ US$10m total size 2023 HBM903
Slide 30: Multimodal and Multidisciplinary Collaborations Extended to Top Partners
Multimodal and Multidisciplinary Collaborations Extended to Various Top International / Domestic Partners Collaboration Areas Types of partners have been increasingly diversified ADC Cell Multimodal and Multidisciplinary mRNA Therapies 多 Monoclonal Immune 领 / bispecific 域 antibody Cell ADC Collabora
Slide 31: Financial Highlights: Sizable Net Profits Achieved for the First Time
Financial Highlights: Sizable Net Profits Achieved for the First Time Ms. Lisa Tong Head of Finance
Slide 32: Sizable and Quality Net Profits Achieved for the First Time
Sizable and Quality Net Profits Achieved for the First Time Continued Strong Revenue Growth Achieved in FY23 Sizable and Quality Net Profits Realized for FY23 • Revenue achieved Exponential Growth from 2021 • We achieved Net Profits on annual basis for the to 2023 FIRST Time in corporate history, 4
Slide 33: Robust Cash Reserve via Efficient Cost Control and Sizable Net Profits
Robust Cash Reserve via Efficient Cost Control and Sizable Net Profits Realized in FY23 Significant Cost Saving from Efficient Management Robust Cash Reserve （Unit: RMB Billion) R&D Expense (Unit: RMB Billion ） Admin Expense 1.36 Selling Expense 1.22 11.5 HBM 9033 1.00 -59% 9.6 4.7 3.2 1.9 1.4 - 0.1
Slide 34: Outlook: Advance Technology Innovation and Focus on Unmet Medical Needs
Outlook： Advance Technology Innovation and Focus on Unmet Medical Needs Dr. Jingsong Wang Founder, Chairman of the Board and Chief Executive Officer
Slide 35: FY24 Catalysts and Milestones
FY24 Catalysts and Milestones Clinical Stage Assets Technology Platform HBM 9161: BLA re-submission Platform upgrade: HBM 4003: initiation of pivotal study, indication HCAb+ / mRNA / CAR-T / AI … expansion Bispecific / multi-specific antibody HBM 1020: initial safety data readout Applica
Slide 36: Outlook (FY24 and Beyond): Advance Technology Innovation and Focus on Unmet Medical Needs
Outlook (FY24 and Beyond): Advance Technology Innovation and Focus on Unmet Medical Needs Building“HCAb Plus”Ecosystem by Connecting Global Resources • Multiple best-in-class pipelines • Build antibody pipelines focusing on tumor immunotherapy while diversifying into non- oncology • Advance several
Slide 37: Q&A
Q&A Contact us at： IR@harbourbiomed.com